Related Experiment Video

Updated: Apr 1, 2026

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment
06:47

Effects of Exposure of Formaldehyde to a Rat Model of Atopic Dermatitis Induced by Neonatal Capsaicin Treatment

Published on: September 27, 2017

10.3K

Tapinarof Versus Crisaborole for Pediatric Atopic Dermatitis: A Systematic Review and Meta-Analysis

Wejdan Alhusaini1, Sara Alghamdi2, Waad Almutairy3

  • 1Pediatrics Infectious Diseases Consultant, University of Jeddah, Jeddah, Saudi Arabia.

Dermatology Practical & Conceptual
|March 30, 2026
PubMed

Insights

Crisaborole and tapinarof are effective nonsteroidal treatments for atopic dermatitis (AD). This review found no significant differences in safety or efficacy between these two topical medications for mild-to-moderate AD.

Area of Science:

  • Dermatology
  • Pharmacology
  • Clinical Research

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin condition impacting quality of life.
  • Nonsteroidal topical agents like crisaborole and tapinarof offer alternatives to corticosteroids for AD management.
  • These agents provide targeted anti-inflammatory effects with potentially fewer systemic side effects.

Purpose of the Study:

  • To systematically review and compare the safety and efficacy of crisaborole versus tapinarof.
  • To evaluate these nonsteroidal treatments in patients with mild-to-moderate atopic dermatitis.

Main Methods:

  • A systematic search identified 24 studies from 510 initial records.
  • Included studies comprised a pooled sample of 8,218 patients.
  • Efficacy was assessed using Investigator's Static Global Assessment (ISGA) and Eczema Area and Severity Index (EASI); safety was based on adverse event incidence.

Main Results:

  • 61% of crisaborole patients and 49% of tapinarof patients achieved ISGA 0-1 (P=0.192).
  • 60% of crisaborole patients and 66% of tapinarof patients showed EASI improvement (P=0.293).
  • No statistically significant differences in efficacy or safety were observed between the two treatments; rare severe events and discontinuations occurred for both.

Conclusions:

  • Both crisaborole and tapinarof demonstrate safe and effective management for mild-to-moderate atopic dermatitis.
  • The choice between crisaborole and tapinarof can be individualized based on patient preference, tolerability, and specific clinical situations.
  • Further research may explore long-term outcomes and comparative effectiveness in diverse patient populations.
Abstract

More Related Videos

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.8K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.7K

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
732
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
374
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
464
Antifungal Agents01:15

Antifungal Agents

Amphotericin B is a broad-spectrum antifungal agent that exploits structural differences between fungal and mammalian cell membranes. Its amphipathic structure—featuring a hydrophobic polyene-lactone ring and a hydrophilic region containing mycosamine and carboxylic acid groups—enables selective binding to ergosterol, a sterol predominantly found in fungal plasma membranes. This selective interaction underlies the drug’s antifungal activity, although weak binding to...
45
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
769